Differential activation and redistribution of c-Src and Fyn in platelets, assessed by MoAb specific for C-terminal tyrosine-dephosphorylated c-Src and Fyn  by Wu, Yi et al.
Di¡erential activation and redistribution of c-Src and Fyn in platelets,
assessed by MoAb speci¢c for C-terminal tyrosine-dephosphorylated
c-Src and Fyn
Yi Wu a, Yukio Ozaki a;*, Katsue Inoue a, Kaneo Satoh a, Tsukasa Ohmori a,
Yutaka Yatomi a, Koji Owada b
a Department of Clinical and Laboratory Medicine, Yamanashi Medical University, Tamaho, Nakakoma, Yamanashi 409-3898, Japan
b Institute of Molecular and Cellular Biology for Pharmaceutical Sciences, Kyoto Pharmaceutical University, 607-8412 Kyoto, Japan
Received 29 November 1999; received in revised form 21 February 2000; accepted 15 March 2000
Abstract
Tyrosine kinases, c-Src and Fyn, in their active form, have their C-terminal tyrosine residue dephosphorylated. In this
study, we used clone 28, a monoclonal antibody (MoAb) that recognizes dephosphorylated C-terminal tyrosine of c-Src and
Fyn, to investigate the mode of activation and mobilization of these kinases. Independently of integrin KIIbL3 signaling, the
Fyn activity increased by 8.3-fold 5 s after stimulation with 20 WM TRAP (thrombin receptor agonist peptide), while that of
c-Src increased only by 2.9-fold 15 s after stimulation. Both c-Src and Fyn translocated to the Triton-insoluble cytoskeletal
fraction in an aggregation-dependent manner. Five minutes after TRAP-stimulation, 85% of Fyn translocated to the
cytoskeleton, while only about 20% of c-Src was recovered in this fraction. The Triton-insoluble fraction was further
fractionated by RIPA (radioimmunoprecipitation assay) buffer containing 0.1% SDS. While active c-Src was predominantly
present in the Triton-insoluble/RIPA-insoluble fraction, clone 28-negative c-Src was present in the Triton-insoluble/RIPA-
soluble fraction. On the other hand, Fyn was present only in the Triton-insoluble/RIPA-insoluble fraction. These findings
suggest that the mode of activation and redistribution into the cytoskeleton differs between c-Src and Fyn, and that clone 28
provides a useful tool for investigating the activation and mobilization of Src family tyrosine kinases. ß 2000 Elsevier
Science B.V. All rights reserved.
Keywords: Platelet ; Tyrosine kinase; c-Src; Fyn; Tyr-530 dephosphorylation; Thrombin
1. Introduction
Increasing lines of evidence suggest that protein
tyrosine phosphorylation catalyzed by tyrosine ki-
nases plays an important role in many aspects of
functional regulation, especially those related to
growth and di¡erentiation. Platelets do not prolifer-
ate or di¡erentiate, but possess a high level of tyro-
sine kinase activity. To date, several tyrosine kinases,
Syk, FAK, c-Src, Fyn, Lyn, Lck, and Yes, have been
found in platelets. c-Src, Fyn, Lyn, Lck, and Yes
belong to the Src family, while Syk and FAK have
structures distinct from the Src family. c-Src, which
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constitutes as much as 0.4% of the total platelet pro-
teins, can be activated by various agonists, such as
thrombin and collagen [1^5]. While its precise role in
platelet function remains elusive, c-Src is suggested
to contribute to the consolidation of platelet aggre-
gate formation.
Tyrosine-530 (Tyr-530) phosphorylation of c-Src
in human cells (Tyr-527 in mouse) has a negative-
regulatory e¡ect on its own kinase activity [6,7]. It
is suggested that the majority of c-Src molecules in
resting platelets are inactive and have their Tyr-530
phosphorylated, which is attributed to the action of
Csk [8^10]. Upon stimulation, c-Src is dephosphory-
lated at Tyr-530 by tyrosine phosphatases, possibly
PTP1C or PTP1D, resulting in its activation [11,12].
The activated c-Src then autophosphorylates its Tyr-
419, which further elevates the c-Src tyrosine kinase
activity.
So far, three methods have been used to evaluate
the activity of Src family tyrosine kinases. One is the
use of anti-phosphotyrosine monoclonal antibodies
(MoAbs) to detect the changes of c-Src tyrosine
phosphorylation. However, since c-Src has two tyro-
sine residues which can be phosphorylated di¡eren-
tially, it is often di⁄cult to evaluate the c-Src activity
by this method. The second one is the in vitro kinase
assay which employs [32P]ATP and appropriate sub-
strates. While this method can evaluate the overall
tyrosine kinase activity, it cannot delineate distinc-
tively the phosphorylated state of Tyr-530 or Tyr-
419. CNBr-cleavage of c-Src after 32P-labelling can
give clues to this issue. However, this method re-
quires a relatively long time and elaborate skill. Re-
cently, Kawakatsu et al. have generated a new
MoAb, termed ‘clone 28’, which selectively recog-
nizes a region adjacent to dephosphorylated Tyr-
530 in the C-terminal regulatory domain of c-Src
[13]. The amino acid sequence adjacent to Tyr-530
of Fyn is same as that of c-Src, except for that serine
525 is substituted by alanine [14]. Hence, this MoAb
may also be used to detect the active form of Fyn,
as well as c-Src, and may o¡er a reliable and simple
tool for evaluating their activated state. In the
present study, by the use of clone 28, we have inves-
tigated the activation and subcellular redistribution
of c-Src and Fyn upon thrombin receptor stimula-
tion in platelets, and have found several distinct fea-
tures.
2. Materials and methods
2.1. Materials
Clone 28 was generated as described previously
[13]. The following materials were obtained from
the indicated suppliers, respectively: anti-c-Src
MoAb (Upstate Biotechnology, Lake Placid, NY);
anti-Fyn MoAb, peroxidase-conjugated goat anti-
rabbit IgG (Santa Cruz, CA); anti-Csk MoAb,
(Transduction Laboratories, Lexington, KY); Gly-
Arg-Gly-Asp-Ser (GRGDS) peptide (Peptide Insti-
tute, Osaka, Japan); protein A-Sepharose 4B (Phar-
macia Biotech, Uppala, Sweden); peroxidase-conju-
gated goat anti-mouse IgG (Cappel, Durham, NC);
control mouse IgG (Zymed, South San Francisco,
CA); ECL chemiluminescence reaction reagents
(Amersham, Buckinghamshire, UK); bovine serum
albumin (BSA), prostaglandin I2 (PGI2), phenyl-
methylsulfonyl £uoride (PMSF), Na3VO4, and Tri-
ton X-100 (Sigma, St. Louis, MO); [Q-32P]ATP (Du
Pont-New England Nuclear, MA). Thrombin recep-
tor agonist peptide (TRAP) was a kind gift of Dr.
Junichi Kambayashi (Osaka University, Osaka, Ja-
pan).
2.2. Platelet preparation and stimulation
Venous blood was obtained from healthy, drug-
free volunteers and platelets were prepared as previ-
ously described [15] and adjusted to a ¢nal concen-
tration of 1U109 cells per ml. Platelets were acti-
vated with TRAP (20 WM) at 37‡C under constant
stirring at 1000 rpm in an aggregometer (Kowa, To-
kyo, Japan).
2.3. Platelet lysis and subcellular fractionation
After the indicated time frame of activation, plate-
lets were lysed with an equal volume of 2Uice-cold
lysis bu¡er (2% Triton X-100, 100 mM Tris/HCl, pH
7.4, 2.0 mM EGTA, 2.0 mM PMSF, 2.0 mM
Na3VO4, and 100 Wg/ml of leupeptin) and kept on
ice for 30 min. All subsequent steps were performed
at 4‡C. The lysates were centrifuged at 15 000Ug for
4 min, and the resulting supernatant (the Triton-
soluble fraction) was collected. After washing, the
pellet (the Triton-insoluble fraction) was solubilized
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in 1USDS sample bu¡er. Alternatively, the pellet
was homogenized in RIPA bu¡er (1% Triton X-
100, 1% sodium deoxycholate, 0.1% sodium dodecyl
sulfate (SDS), 158 mM NaCl, 10 mM Tris (pH 7.2),
1.0 mM EGTA, 100 Wg/ml of leupeptin, 1.0 mM
PMSF, 1.0 mM Na3VO4) for 30 min. This lysate
was centrifuged at 15 000Ug for 4 min. The super-
natant (the Triton-insoluble/RIPA-soluble fraction)
was removed, and the pellet (the Triton-insoluble/
RIPA-insoluble fraction) was solubilized in 1USDS
sample bu¡er.
2.4. Immunoprecipitation of platelet lysates
c-Src and Fyn were immunoprecipitated from
soluble fractions according to the previous methods
[16]. The immune complexes were washed three times
with 1Uice-cold lysis bu¡er for the Triton-soluble
fraction or with RIPA bu¡er for the Triton-insolu-
ble/RIPA-soluble fraction. The immunoprecipitate
was then subjected to Western blotting. In some ex-
periments, c-Src or Fyn immunoprecipitation was
performed under the condition that inhibited platelet
aggregation, since Src kinases are known to trans-
locate to the cytoskeleton in an aggregation-depen-
dent manner [17,18]. Under the same condition, in
order to obtain pure Tyr-530-dephosphorylated c-Src
and Fyn, reimmunoprecipitation experiments were
further performed as described by Berditchevski et
al. [19] with minor modi¢cations. Brie£y, the c-Src
and Fyn immunoprecipitates obtained from the Tri-
ton-soluble fraction were solubilized with 1Uice-cold
lysis bu¡er containing 2% SDS and rotated at 4‡C
for 30 min, then centrifuged at 15 000Ug for 2 min.
The supernatant was diluted 40 times with 1Ulysis
bu¡er without SDS, followed by reimmunoprecipita-
tion of activated c-Src and Fyn with clone 28, respec-
tively. The immunoprecipitated proteins were de-
tected by Western blotting using clone 28, and
quanti¢ed with a PDI420oe scanner (PDI, New
York, USA).
2.5. Immunoprecipitation kinase assay
The immunoprecipitates were washed three times
with 1Ulysis bu¡er, and once with HEPES bu¡er (10
mM HEPES/NaOH, 1 mM Na3VO4, pH 8.0), fol-
lowed by further processing for an in vitro kinase
assay according to the method described previously
[16]. The beads were incubated with 50 Wl of kinase
reaction bu¡er (100 mM HEPES/NaOH, pH 8.0,
5 mM MnCl2, 50 mM MgCl2) containing 10 Wg of
acid-treated enolase. The reaction was initiated by
the addition of 2.0 Wmol [Q-32P]ATP (10 WCi). After
10 min of incubation at 20‡C, reactions were stopped
by the addition of Laemmli’s bu¡er and then sub-
jected to boiling for 3 min. After Western blotting,
the membrane was treated with 1 M KOH for 60
min, then dried. The radioactivity was quanti¢ed
with a BAS-2000 phosphor-image analyzer (Fuji
Film, Tokyo, Japan).
3. Results and discussion
3.1. Clone 28 recognized Fyn as well as c-Src in
human platelets
LEDYFTSTEPQYQPGENL, which represents the
amino acids 519^536 of human c-Src, was used as
an immunogen for the generation of clone 28.
Kawakatsu et al. have shown that clone 28 selec-
tively recognizes the active form of c-Src, whose
Tyr-530 is dephosphorylated, but not that of Tyr-
530-phosphorylated in platelets [13]. The speci¢city
of clone 28 for the active form of c-Src has also
been con¢rmed in ¢broblasts [20]. The C-terminal
amino acid sequence (LEDYFTATEPQYQPGENL,
amino acids 519^536) of another Src family member,
Fyn, is the same as that of c-Src, except for that
serine 525 is replaced by alanine [14]. We asked
whether clone 28 can also recognize Fyn in human
platelets. As shown in Fig. 1, not only c-Src (lane 1),
but also Fyn (lane 2), immunoprecipitated by the
corresponding MoAbs, could be speci¢cally detected
by clone 28 in Western blotting. The proteins immu-
noprecipitated by clone 28 also reacted with anti-c-
Src MoAb or anti-Fyn MoAb (lanes 4 and 5). How-
ever, clone 28 did not recognize other kinases of Src
family, such as pp62yes, pp56lck, and pp53/56lyn (data
not shown), whose C-terminal amino acid sequences
are distinct from those of c-Src and Fyn. Obviously,
Clone 28 is sensitive enough to react with Fyn as well
as c-Src, not only in immunoprecipitation, but in
Western blotting. In this study, we used clone 28
for detecting Tyr-530-dephosphorylated c-Src and
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Fyn, thereby comparing their di¡erences in activa-
tion and subcellular redistribution upon thrombin
receptor stimulation.
3.2. Fyn is activated earlier and to a higher extent
than c-Src upon TRAP stimulation
Several lines of evidence have suggested that
thrombin stimulation may induce c-Src activation
in platelets [1^4], and its translocation to the cyto-
skeleton [15,17,18,21,22]. Using two-dimensional
tryptic phosphopeptide mapping and CNBr cleavage
techniques, it has been shown that dephosphoryla-
tion of Tyr-530 is an initial change of c-Src activa-
tion upon thrombin stimulation in platelets [3,4].
Although translocation of c-Src to the cytoskeleton
is dependent upon platelet aggregation and integrin
KIIbL3 signaling [17,18], c-Src activation appears to
be independent of these processes [1,4]. Hence, in
order to evaluate the overall c-Src kinase activity
within the cells, platelets were pretreated with 500
WM GRGDS and 200 WM EGTA to inhibit platelet
aggregation and translocation of c-Src to the Triton-
insoluble cytoskeleton. We ¢rst performed a single
step immunoprecipitation using anti-c-Src MoAb.
Brie£y, after stimulation with 20 WM TRAP, c-Src
was immunoprecipitated from the Triton-soluble ly-
sates, then subjected to Western blotting with clone
28. However, no signi¢cant change in Tyr-530-de-
phosphorylation of c-Src could be observed (data
not shown). We assumed that clone 28, when applied
to Western blotting, could not completely di¡erenti-
ate dephosphorylated Tyr-530 from phosphorylated
one in the presence of the excessive amount of inac-
tive c-Src. Hence, we performed a double-step immu-
noprecipitation method to resolve this issue. Brie£y,
the immunoprecipitated c-Src was resolubilized, and
was further subjected to the reimmunoprecipitation
with clone 28 to capture active c-Src as described in
the Section 2. The samples were subjected to Western
blotting with clone 28 to detect the recovery of active
c-Src. This method augmented the sensitivity and
speci¢city of this antibody for detecting a small
amount of activated c-Src, even in the presence of
excessive inactive forms. As shown in Fig. 2A, c-Src
was dephosphorylated on Tyr-530 as early as 5 s
after TRAP-stimulation. Dephosphorylation of Tyr-
530 peaked at 15 s with a 2.9-fold increase (Fig. 2C),
then returned to the original level at 1 min.
Previous attempts to detect changes in Fyn activity
in thrombin-stimulated platelets were all without suc-
cess [23^25]. In these studies, Fyn activity was mea-
sured at time frames longer than 30 s after thrombin
stimulation, and platelets were allowed to aggregate
[23,24]. In view of the rapid mode of c-Src activation
and translocation to the cytoskeleton, we were in-
spired to re-examine Fyn activation in the same con-
dition used for c-Src, i.e. at earlier time points after
stimulation, and also in the absence of aggregation.
Interestingly, as detected by the same double-step
immunoprecipitation method with clone 28, there
was a maximum increase of 8.3-fold in Tyr-530-de-
phosphorylated Fyn as early as 5 s after TRAP stim-
ulation, compared with the resting state, and it rap-
idly decreased thereafter (Fig. 2B,C). The in vitro
kinase assays gave results essentially similar, which
con¢rmed that the Fyn activity peaks 5 s after TRAP
stimulation in GRGDS-pretreated platelets (Fig. 3).
Our ¢ndings suggest that Fyn is activated upon
TRAP stimulation more rapidly and more markedly
than c-Src, independently of integrin KIIbL3 signal-
ing in human platelets. To the best of our knowl-
edge, this is the ¢rst report to demonstrate that
Fyn is activated in response to thrombin receptor
stimulation in platelets. In ¢broblasts, it was also
reported that Fyn activation occurs at a time course
earlier than c-Src [26]. While the abundance of Fyn
in platelets is approximately 5- to 10-fold lower than
that of c-Src [24], Fyn also may play an important
Fig. 1. Fyn as well as c-Src can be recognized by clone 28 in
human platelets. Platelet lysates were immunoprecipitated by
anti-c-Src MoAb (lane 1), anti-Fyn MoAb (lane 2), control
mouse IgG (lane 3), and clone 28 (lanes 4^6). The immune
complexes were subjected to Western blotting by clone 28 (lanes
1^3), anti-c-Src MoAb (lane 4), anti-Fyn MoAb (lane 5), and
mouse IgG (lane 6).
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role in tyrosine phosphorylation events in human
platelets, particularly in the early phase.
3.3. Distinct subcellular redistribution of c-Src and
Fyn upon TRAP stimulation
It has been suggested that Src kinase activation is
closely related to its association with the detergent-
insoluble matrix [27]. Since we found that c-Src and
Fyn are activated with distinct time courses and ex-
tents, we investigated whether their kinetics of trans-
location from the Triton-soluble fraction to the Tri-
ton-insoluble fraction are also distinct. Platelets were
activated by TRAP and allowed to aggregate. After
various time frames, platelets were lysed with lysis
bu¡er, and the amount of c-Src and Fyn in these
two fractions was analyzed by Western blotting
with the corresponding MoAbs. As early as 5 s after
TRAP stimulation, c-Src and Fyn translocated to the
Triton-insoluble fraction in a time- and aggregation-
dependent manner (Fig. 4A,B). At the same time,
there was a parallel decrease in the recovery of
c-Src and Fyn in the Triton-soluble fraction. Five
minutes after stimulation, the majority of Fyn (ap-
proximately 85% of its total population) redistributed
to the Triton-insoluble fraction, whereas only about
20% of c-Src relocated to this fraction. The latter
Fig. 3. Time course of Fyn activation assessed by in vitro ki-
nase assay. As described in the legend for Fig. 2, platelets pre-
treated with GRGDS and EGTA were stimulated by 20 WM
TRAP for the indicated time frames, and reactions were termi-
nated with lysis bu¡er. Fyn was isolated by immunoprecipita-
tion with a corresponding MoAb. The immunoprecipitates were
divided into two: one half was subjected to an in vitro kinase
assays using enolase as an exogenous substrate, the proteins
were separated under reducing conditions by 8% SDS^PAGE
and quanti¢ed with a BAS 2000 Phosphorimager (A); the other
half was subjected to Western blotting with anti-Fyn MoAb, to
con¢rm the recovery of Fyn (B). In both A and B, the numbers
on the bottom show time in seconds. The arrows represent the
band presumably derived from IgG heavy chains. The data are
representative of three experiments.
Fig. 2. Dephosphorylation of c-Src and Fyn at Tyr-530 upon
TRAP-stimulation evaluated by clone 28. Washed Platelets
(1U109/ml) pretreated with 500 WM GRGDS and 200 WM
EGTA were stimulated with 20 WM TRAP for the indicated
time intervals (0^60 s), then lysed with Triton X-100-containing
lysis bu¡er. The Triton-soluble fraction was divided into two
equal volumes, subjected to c-Src and Fyn immunoprecipita-
tions, respectively. After three washes with 1Ulysis bu¡er, the
target antigen, c-Src and Fyn, were eluted from the primary
antibody^bead conjugates by 1Ulysis bu¡er containing 2%
SDS. The mixture was diluted 40 times by 1Ulysis bu¡er, fol-
lowed by the re-immunoprecipitation with clone 28. The pro-
teins were separated by SDS^PAGE and transferred onto a ni-
trocellulose membrane, which was immunoblotted with clone 28
(A,B). The dynamic change of Tyr-530-dephosphorylation of c-
Src in A and of Fyn in B was quanti¢ed with densitometric
scanning and was represented as percent increase over the origi-
nal level at 0 s (C). The data are representative of three experi-
ments. Numbers on the bottom show time in seconds. The ar-
rows represent the bands presumably derived from the heavy
chains of immunoglobulin (Ig) G.
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¢nding was consistent with previous observations
[17,22].
To clarify further the redistribution kinetics of ac-
tive c-Src and Fyn in human platelets, each kinase
was immunoprecipitated in the Triton-soluble frac-
tion of TRAP-stimulated platelets, followed by clone
28 Western blotting to detect their active form in the
immunoprecipitates. As shown in Fig. 5, in the Tri-
ton-soluble fraction, there was a rapid and transient
increase in Tyr-530-dephosphorylated c-Src and Fyn
5 s after stimulation, followed by a drastic decrease
after 15 s. The extent by which clone 28-recognizable
c-Src or Fyn disappeared from the Triton-soluble
fraction was greater than the loss of the overall
c-Src or Fyn population, indicating that the active
forms of c-Src and Fyn more preferentially move
to the Triton-insoluble fraction. In the pressure-over-
loaded myocardium, a signi¢cant amount of Tyr-
530-dephosphorylated c-Src also associated with the
cytoskeletal fraction, as detected by clone 28 MoAb
[28].
3.4. Active c-Src and Fyn speci¢cally translocate to
the RIPA-insoluble fraction, whereas inactive
c-Src is present in the Triton-insoluble/RIPA-
soluble fraction
Treatment of cells with non-ionic and ionic deter-
gents has been widely used to reveal the architecture
of cytoskeletal framework and its relation to other
subcellular components [29^31]. In order to evaluate
precisely the relocation of the Src family kinases to
the Triton-insoluble cytoskeletal fraction, this frac-
tion of aggregated platelets was further fractionated
Fig. 4. Distinct existence of c-Src and Fyn in the Triton-soluble and -insoluble fractions. The left panels show Western blots of Tri-
ton-soluble and Triton-insoluble fractions of whole lysates of aggregated platelets stimulated with 20 WM TRAP for the indicated time
intervals (s), probed with anti-c-Src (A), anti-Fyn (B) MoAbs. The right panels indicated densitometric quanti¢cation of the amounts
(%) of c-Src (C) and Fyn (D) in the Triton-soluble and Triton-insoluble fractions. The data are representative of three experiments.
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by RIPA bu¡er into two portions, one that can be
solubilized by RIPA bu¡er (Triton-insoluble/RIPA-
soluble fraction) and the other resistant to RIPA
bu¡er (Triton-insoluble/RIPA-insoluble fraction).
The Triton-insoluble/RIPA-soluble fraction was
then subjected to immunoprecipitation with anti-c-
Src or anti-Fyn MoAb, followed by Western blotting
with the same antibody, or clone 28 to detect their
active forms. Although the nature of these two frac-
tions remains to be determined, they apparently rep-
resent two forms of Triton-insoluble cytoskeletal
fractions, one with comparatively loose complex for-
mation, and the other possibly with tightly packed
network formation of cytoskeletal proteins. As
shown in Fig. 6, while a relatively large amount of
c-Src translocated to the Triton-insoluble/RIPA-solu-
ble fraction upon TRAP-stimulation, Fyn was virtu-
ally absent in this fraction. The c-Src molecules
present in the Triton-insoluble/RIPA-soluble fraction
were negative for clone 28, suggesting that the ma-
jority of them were in the inactive state, i.e. their
Tyr-530 is phosphorylated and binds to their own
SH2 domain to ¢rm a closed conformation. On the
other hand, both Fyn and c-Src translocated to Tri-
ton-insoluble/RIPA-insoluble fraction upon platelet
activation. Although Western blotting with clone 28
cannot di¡erentiate c-Src from Fyn, it is most likely
that the active forms of c-Src and Fyn are both
present in this Triton-insoluble/RIPA-insoluble frac-
tion, since they disappeared from the Triton-soluble
fraction upon aggregation. Horvath et al. have found
that a relatively large amount of c-Src with increased
Fig. 5. Dynamic change in Tyr-530-dephosphorylated c-Src and
Fyn in the Triton-soluble fractions from TRAP-stimulated
platelets. Both c-Src and Fyn were immunoprecipitated in the
Triton-soluble lysates from TRAP-stimulated platelets, which
were not pretreated with GRGDS plus EGTA. The c-Src and
Fyn immunoprecipitates were analyzed by Western blots with
the corresponding MoAbs and clone 28, respectively. Numbers
on the bottom show time in seconds. The data are representa-
tive of three experiments.
Fig. 6. Solubility of the cytoskeleton-associated Tyr-530-dephosphorylated c-Src and Fyn in RIPA bu¡er. Platelets were stimulated,
lysed, and the lysates were fractionated as described in Section 2. The Triton-insoluble fractions were further lysed in RIPA bu¡er.
Both c-Src and Fyn were immunoprecipitated from the Triton-insoluble/RIPA-soluble lysates, respectively. The Triton-insoluble/RIPA-
insoluble pellets were heated in 1USDS sample bu¡er. The soluble fractions or pellets were immunoblotted with clone 28 and anti-c-
Src or anti-Fyn MoAb. Numbers on the bottom show time in seconds. The data are representative of three experiments.
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activity remained in the ionic detergent-insoluble cy-
toskeleton [17], with which our ¢ndings are in ac-
cord.
v-Src, which lacks C-terminal Tyr, associates with
the cytoskeleton via its free SH2 domain [27,29,32],
since the association is prevented if its SH2 domain is
deleted or mutated (R175K). The normal cellular
counterpart, c-Src has its SH2 domain blocked by
the negative regulatory phosphorylated Tyr-530, pre-
venting interaction with cytoskeletal proteins. In
Src3=3 ¢broblasts over-expressing mutated Src A
(Y527F), the detergent-insoluble Src A protein was
found predominantly in focal adhesions, suggesting
that mutation of Y527 with the free SH2 domain is
su⁄cient to cause redistribution of c-Src from endo-
somal membrane to focal adhesions [33]. By analogy,
we assume that when Src kinases are dephosphory-
lated at C-terminal Tyr upon activation, accompa-
nied by the SH2 domain liberation, the free SH2
domains play a major role in recruiting c-Src and
Fyn to the cytoskeleton in human platelets. Our re-
sults suggest that such interaction is ionic detergent-
resistant and of high strength, which may contribute
to stable transduction of Src kinase-mediated signal-
ing, and form a continuous three-dimensional cyto-
skeletal framework. It still remains to be determined
what cytoskeletal proteins associate with c-Src and
Fyn in platelets.
The appearance of clone 28-negative c-Src, but not
Fyn in the RIPA-soluble fraction is also of interest.
Although active Src kinases associate with cytoskel-
eton upon activation, the translocation of their inac-
tive forms to the cytoskeleton has not been totally
ruled out. In resting platelets, a part of inactive c-Src
associates with subcellular components, such as in-
tegrin KIIbL3 [34,35]. In the process of platelet ag-
gregation when a large number of subcellular com-
ponents including integrin KIIbL3 are incorporated
into cytoskeletal compartments, it is possible that
these inactive c-Src molecules are passively trans-
ported into the Triton-insoluble cytoskeletal fraction.
Since they have no free SH2 domains by which to
bind to phosphorylated tyrosine of other proteins, it
may be that they are sensitive to ionic detergents,
and solubilized in the RIPA bu¡er. In contrast, there
may be no such passive transport of Fyn, resulting in
the absence of Fyn in the RIPA soluble fraction.
Alternatively, it is also possible that only the active
c-Src translocates to the Triton-insoluble fractions,
but later some undergo rephosphorylation with re-
sultant deactivation. Tyr-530 of c-Src is phosphory-
lated by its negative regulatory kinase Csk, and it is
suggested that it also associates with the Triton-in-
soluble fractions in other cells [36,37]. In this study,
we con¢rmed that Csk translocates to the RIPA-in-
soluble fraction in TRAP-stimulated human platelets
(data not shown). Thus, a part of c-Src with its Tyr-
530 dephosphorylated may be rephosphorylated at
Tyr-530 by this regulatory kinase when c-Src and
Csk are recruited to the cytoskeleton. After Tyr-
530-rephosphorylation of c-Src, its SH2 domain
may bind to its own phosphorylated Tyr-530 (Tyr-
527 in mouse), hampering the ¢rm association with
other proteins, with resultant solubility in RIPA
bu¡er. In Csk-de¢cient ¢broblasts, c-Src was also
found predominantly in focal adhesions, con¢rming
that phosphorylation of Tyr-527, regulated by Csk,
a¡ects the cellular location of c-Src [33]. In contrast
to c-Src, it is possible that Csk in the Triton-insolu-
ble fraction may not catalyze Fyn rephosphorylation,
and thus, Fyn ¢rmly attaches to this fraction. Ki-
nases responsible for Fyn rephosphorylation have
not been determined to date.
In conclusion, we found in the present study that
clone 28 which recognizes the active form of c-Src
can also serve to evaluate the active form of Fyn.
Upon TRAP stimulation, Fyn is activated more rap-
idly and to a higher extent than that of c-Src. These
two kinases translocate to the Triton-insoluble frac-
tions in an aggregation-dependent manner, with dif-
ferent kinetics. The association of their active forms
with cytoskeleton is resistant to ionic detergent treat-
ment.
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